 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- elexacaftor (VX-445) / Vertex, vanzacaftor (VX-121) / Vertex
Effects of elexacaftor (VX-445) and vanzacaftor (VX-121) on KCNT1 (slack) and KCNT2 (slick) potassium channels () - Sep 4, 2024 - Abstract #NACFC2024NACFC_1018;
The term "slack" refers to the acronym "sequence like a calcium-activated K+ channel" and was given to this channel when it was discovered that a portion of the pore domain and the entire S6 transmembrane segment is similar to BKCa. The channels have only 7% similarity, overall.
- vanzacaftor (VX-121) / Vertex
Differential effects of (S)- and (R)-vanzacaftor on BKCa potentiation and CFTR correction () - Sep 4, 2024 - Abstract #NACFC2024NACFC_1016;
Incubation in (S)-VX-121 converts a population of band B F508del CFTR to band C, consistent with F508del CFTR correction, but (R)-VX-121 fails to correct F508del CFTR. (S)- and (R)-VX-121 both stimulate K+ secretion across HBECs and potentiate BKCa channels during whole-cell patch-clamp recording.
- elexacaftor (VX-445) / Vertex, Kalydeco (ivacaftor) / Vertex, vanzacaftor (VX-121) / Vertex
Enhancing apical loop currents in airway epithelia carrying minimal function CFTR mutations () - Sep 4, 2024 - Abstract #NACFC2024NACFC_902;
(S)- and (R)-VX-121 both stimulate K+ secretion across HBECs and potentiate BKCa channels during whole-cell patch-clamp recording. Potentiation of BK was assessed using elexacaftor (VX-445; 10
- || vanzacaftor/tezacaftor/deutivacaftor (VX-121/VX-661/VX-561) / Vertex, vanzacaftor (VX-121) / Vertex
New P1 trial, Combination therapy: A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA) (clinicaltrials.gov) - Mar 12, 2024
P1, N=34, Not yet recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
- ||| vanzacaftor (VX-121) / Vertex
Trial completion, Monotherapy: An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants (clinicaltrials.gov) - Jul 14, 2023
P1, N=56, Completed, Sponsor: Vertex Pharmaceuticals Incorporated
Potentiation of BK was assessed using elexacaftor (VX-445; 10 Active, not recruiting --> Completed
- || vanzacaftor (VX-121) / Vertex
Enrollment closed, Monotherapy: An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants (clinicaltrials.gov) - Jun 12, 2023
P1, N=56, Active, not recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| vanzacaftor (VX-121) / Vertex
New P1 trial, Monotherapy: An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants (clinicaltrials.gov) - May 19, 2023
P1, N=56, Recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
- Comparing F508del cystic fibrosis transmembrane conductance regulator modulator responses in human primary enteric monolayer and human bronchial epithelial cultures (Exhibition Hall) - Oct 8, 2022 - Abstract #NACFC2022NACFC_1178;
Data presented here compare the sensitivity andassay window of the hPEM model with those of the hBE model. This, alongwith more readily accessible material of a wide genotype range and greaterexpansion capability, makes the hPEM model an attractive platform forassessing CFTR functional rescue in response to novel therapeutic agents.
- | VX-121 / Vertex
Any update on VX-121 triple combo? (Twitter) - Oct 8, 2020
- | VX-121 / Vertex
Has anyone attending #NACFC2020 heard an update on @VertexPharma VX-121 triple combo? (Twitter) - Oct 7, 2020
- ||| vanzacaftor/tezacaftor/deutivacaftor (VX-121/VX-661/VX-561) / Vertex, vanzacaftor (VX-121) / Vertex
Trial completion, Combination therapy: A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (clinicaltrials.gov) - Jan 9, 2020
P2, N=87, Completed, Sponsor: Vertex Pharmaceuticals Incorporated
This, alongwith more readily accessible material of a wide genotype range and greaterexpansion capability, makes the hPEM model an attractive platform forassessing CFTR functional rescue in response to novel therapeutic agents. Active, not recruiting --> Completed
- | vanzacaftor/tezacaftor/deutivacaftor (VX-121/VX-661/VX-561) / Vertex, vanzacaftor (VX-121) / Vertex
Enrollment closed, Combination therapy: A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (clinicaltrials.gov) - Oct 11, 2019
P2, N=87, Active, not recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| vanzacaftor/tezacaftor/deutivacaftor (VX-121/VX-661/VX-561) / Vertex, vanzacaftor (VX-121) / Vertex
Enrollment open, Combination therapy: A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (clinicaltrials.gov) - Jun 3, 2019
P2, N=81, Recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| vanzacaftor (VX-121) / Vertex
Trial completion: Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis (clinicaltrials.gov) - Jun 2, 2019
P1/2, N=114, Completed, Sponsor: Vertex Pharmaceuticals Incorporated
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| vanzacaftor/tezacaftor/deutivacaftor (VX-121/VX-661/VX-561) / Vertex, vanzacaftor (VX-121) / Vertex
New P2 trial, Combination therapy: A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (clinicaltrials.gov) - Apr 11, 2019
P2, N=81, Not yet recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
- || vanzacaftor (VX-121) / Vertex
Enrollment closed: Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis (clinicaltrials.gov) - Apr 8, 2019
P1/2, N=114, Active, not recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| vanzacaftor (VX-121) / Vertex
New P1/2 trial: Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis (clinicaltrials.gov) - Dec 7, 2018
P1/2, N=132, Recruiting, Sponsor: Vertex Pharmaceuticals Incorporated